References:
1. Kraemer KH, DiGiovanna JJ, Tamura D. Xeroderma Pigmentosum [Internet]. GeneReviews® [Internet]. University of Washington, Seattle; 2022 [cited 2022 May 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1397/
2. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, et al. Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients. J Thorac Oncol. 2011 Dec 1;6(12):2018–26.
3. Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. 2016 Oct;17(5):491–508.
4. Kaloga M, Dioussé P, Diatta BA, Bammo M, Kourouma S, Diabate A, et al. Squamous Cell Carcinoma in African Children with Xeroderma Pigmentosum: Three Case Reports. Case Rep Dermatol. 2016;8(3):311–8.
5. Nair AG, Kaliki S, Mishra DK, Reddy VA, Naik MN. Neoadjuvant chemotherapy for invasive squamous cell carcinoma of the conjunctiva: A case report. Indian J Ophthalmol. 2015 Dec;63(12):927–9.
6. Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol. 2000 Apr;23(2):181–4.
7. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32–4.
8. DeConti RC. Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol. 2012 Apr;39(2):145–9.
9. Sumiyoshi M, Soda H, Sadanaga N, Taniguchi H, Ikeda T, Maruta H, et al. Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum. Intern Med. 2017 Apr 15;56(8):979–82.
10. Carneiro MC, Kimura T de C, Tolentino E de S, Pieralisi N, Veltrini VC. Unusual intraoral cancer with unexpected outcome in a patient with xeroderma pigmentosum: An alert for antineoplastic treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Jan 1;129(1):e1–11.
11. Gilbar PJ, Pokharel K. Severe cisplatin-induced renal toxicity in a patient with xeroderma pigmentosum. J Oncol Pharm Pract. 2022 Mar 1;28(2):466–70.
12. Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer: XPD Haplotype and Lung Cancer. Cancer. 2006 Jun 1;106(11):2421–7.
13. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin–DNA adducts by the mammalian excision nuclease. Biochemistry. 1996 Aug 6;35(31):10004–13.
14. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 Feb 1;33(1):9–23.
15. Hu LB, Chen Y, Meng XD, Yu P, He X, Li J. Nucleotide Excision Repair Factor XPC Ameliorates Prognosis by Increasing the Susceptibility of Human Colorectal Cancer to Chemotherapy and Ionizing Radiation. Front Oncol. 2018;8:290.
16. Fayyad N, Kobaisi F, Beal D, Mahfouf W, Ged C, Morice-Picard F, et al. Xeroderma Pigmentosum C (XPC) Mutations in Primary Fibroblasts Impair Base Excision Repair Pathway and Increase Oxidative DNA Damage. Front Genet. 2020;11:561687.